AbbVie subsidiary Allergan [recently] sued Revance, alleging the company’s proposed frown-line injection daxibotulinumtoxinA infringes several Botox patents. An FDA decision on Revance’s rival drug is “imminent,” AbbVie says in the suit, so the pharma giant is seeking a judgment from the court that its patents will be infringed, plus damages that could include a “reasonable royalty and lost profits.”

For its part, Revance believes the patents at issue “are not infringed upon by Revance or our supply source partner Ajinomoto or are invalid,” a representative said.

Read the full article at